(Q87691736)

English

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer

scientific article published on 15 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

11

object named as

Caicun Zhou

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Mingchuan Zhao

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Yishi Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Weijing Cai

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jiayu Li

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Fei Zhou

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ningning Cheng

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ruixin Ren

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Chao Zhao

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Xuefei Li

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Shengxiang Ren

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Fred R Hirsch

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

15 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

120

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

2299-2307

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28725

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87691736&oldid=2147350488"